PDF(Pubmed)
Abstract：
International guidelines on the treatment of myasthenia gravis (MG) have been published but are not tailored to the Belgian situation. This publication presents recommendations from a group of Belgian MG experts for the practical management of MG in Belgium. It includes recommendations for treatment of adult patients with generalized myasthenia gravis (gMG) or ocular myasthenia gravis (oMG). Depending on the MG-related antibody a treatment sequence is suggested with therapies that can be added on if the treatment goal is not achieved. Selection of treatments was based on the level of evidence of efficacy, registration and reimbursement status in Belgium, common daily practice and the personal views and experiences of the authors. The paper reflects the situation in February 2024. In addition to the treatment considerations, other relevant aspects in the management of MG are addressed, including comorbidities, drugs aggravating disease symptoms, pregnancy, and vaccination. As many new treatments might potentially come to market, a realistic future perspective on the impact of these treatments on clinical practice is given. In conclusion, these recommendations intend to be a guide for neurologists treating patients with MG in Belgium.
摘要：
关于重症肌无力（MG）治疗的国际指南已经发布，但并未针对比利时的情况。本出版物提出了一组比利时MG专家对比利时MG的实际管理的建议。它包括对患有全身性重症肌无力（gMG）或眼部重症肌无力（oMG）的成年患者的治疗建议。根据MG相关抗体,建议治疗序列,如果未实现治疗目标,则可以添加治疗。治疗的选择是基于疗效的证据水平，在比利时的注册和报销状态，常见的日常实践和作者的个人观点和经验。本文反映了2024年2月的情况。除了治疗方面的考虑,解决了MG管理中的其他相关问题，包括合并症,药物加重疾病症状，怀孕,和疫苗接种。由于许多新疗法可能会进入市场，对这些治疗对临床实践的影响给出了一个现实的未来观点。总之,这些建议旨在成为比利时治疗MG患者的神经科医师指南.
